Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 516 results for syndrome

  1. Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes with onset in childhood, for example, myoclonic-astatic epilepsy and Dravet syndrome?

    Question Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes...

    Research recommendation
    Published
    13 August 2021

  2. Fractures (complex): assessment and management (NG37)

    This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.

    NICE guideline
    Last updated
    23 November 2022
    View recommendations

    Sections for NG37

  3. Falls in older people: assessing risk and prevention (CG161)

    This guideline covers assessment of fall risk and interventions to prevent falls in people aged 65 and over. It aims to reduce the risk and incidence of falls and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

    Clinical guideline
    Published
    12 June 2013
    View recommendations

    Sections for CG161

  4. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population...

    Research recommendation
    Published
    12 November 2021

  5. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA322

  6. Learning disabilities: annual TSH test (IND79)

    This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04

    General practice indicators suitable for use outside of QOF
    Last updated
    3 November 2020

  7. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. What is the natural history of post-COVID-19 syndrome?

    NG188/5 Question What is the natural history of post-COVID-19 syndrome? Any explanatory notes(if applicable) Source guidance

    Research recommendation
    Published
    12 November 2021

  9. Interventions to improve CPAP adherence: Which interventions, including behavioural interventions, are most clinically and cost effective to improve adherence to CPAP in people with OSAHS, obesity hypoventilation syndrome (OHS) and COPD–OSAHS (chronic obstructive pulmonary disease–OSAHS) overlap syndrome who have difficulty using CPAP?

    OSAHS, obesity hypoventilation syndrome (OHS) and COPD–OSAHS (chronic obstructive pulmonary disease–OSAHS) overlap syndrome...

    Research recommendation
    Published
    30 September 2021

  10. Pancreatic cancer in adults: diagnosis and management (NG85)

    This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

    NICE guideline
    Published
    7 February 2018
    View recommendations

    Sections for NG85

  11. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)

    This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.

    Clinical guideline
    Last updated
    4 August 2017
    View recommendations

    Sections for CG32

  12. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TS ID 10755]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. NICE CG32 Refeeding Guidelines: Retrospective audit comparing dietetic and medical practice of vitamin prescriptions, blood checks and K+, PO43- & Mg2+ replacement including discharge medications

    April 2018 Refeeding syndrome consists of metabolic changes that occur on the reintroduction of nutrition

    Shared learning
    Published
    18 April 2018

  15. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA191